Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus + Bicalutamide in Asymptomatic mCRPC
NCT00777959Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2008
- Primary completion
- May 2011
- Modality
- Classical Binding Small Molecules
01
Overview
A Phase 2 trial of ridaforolimus in prostate cancer (PCa), sponsored by Merck & Co.. Started Oct 2008; status: completed.
02
Drugs
ridaforolimus
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00777959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777959.